Published

A double-blind, placebo controlled study of the effect of the hallucinogenic 5-HT1A&2A agonist psilocybin on binocular rivalry rate and rhythmicity

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: Social Neuroscience
Date: 2003-01-01
Source: OpenAlex
DOI: Unavailable
PubMed: Unavailable

Authors

O. Carter Shaun P. Collin Felix Hasler George Liu Franz X. Vollenweider John D. Pettigrew

Watch author

Derived topics and classifications

psilocybin Pharmacology Receptor Pharmacology Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Going on Trial: Serotonin drug; psilocybin phase 2; placebo response dataThe Transmitter · 2023-01-01 Neurochemical and behavioural characterisation of the psychedelic 5HT2AR agonist psilocybin in miceNeuroscience Applied · 2022-01-01 Neurobiological and Therapeutic Potential of Psilocybin in Psychiatric DisordersJournal of Pharma Insights and Research. · 2025-10-05 Therapeutic Potential of Fungally Derived Psilocybin Extract in Morphine-Dependent Mice: A Research ProtocolUndergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · 2024-06-10 EPA-1211 - Role of 5-HT2a and mglu2 as a gpcr heterocomplex in antipsychotic actionEuropean Psychiatry · 2013-12-31 Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in HumansPLoS ONE · 2010-12-01 Psychopathological effects of S-ketamine and dimethyltryptamine (DMT) in humans: a double-blind, cross-over human experimental study of the NMDA antagonist and the 5HT2A agonist model of psychosisPharmacopsychiatry · 2005-09-01 Psychedelics produce enduring enhancement of reward responsiveness in male rats.Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology · 2026-07-10